Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

2016268 citationsJournal Article

Authors

Ofri Mosenzon · Hebrew University of Jerusalem

Gil Leibowitz

Deepak L. Bhatt · Brigham and Women's Hospital

Avivit Cahn

Boaz Hirshberg

Cheryl Wei · AstraZeneca (United States)

KyungAh Im · Brigham and Women's Hospital

Aliza Rozenberg · Hebrew University of Jerusalem

Abstract

Treatment with saxagliptin improved ACR, even in the normoalbuminuric range, without affecting eGFR. The beneficial effect of saxagliptin on albuminuria could not be explained by its effect on glycemic control.

Topics & Keywords

Diabetes Treatment and Management Chronic Kidney Disease and Diabetes Hyperglycemia and glycemic control in critically ill and hospitalized patients

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Care

Volume 40, Issue 1, pp. 69-76

DOI: 10.2337/dc16-0621

Field-Weighted Citation Impact: 25.02